Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994171 | 0.96 | TSHR (0.52) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL29026713 | 0.93 | TSHR (0.48) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL24675567 | 0.89 | L3MBTL1 (0.48) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL3269931 | 0.88 | TSHR (0.52) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL20231370 | 0.86 | TSHR (0.50) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL2246824 | 0.85 | L3MBTL1 (0.50) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL4104428 | 0.85 | L3MBTL1 (0.50) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL1469764 | 0.85 | L3MBTL1 (0.50) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL1164446 | 0.85 | L3MBTL1 (0.50) | TSHRTEAD3NAAACA1CA2 | |
| SCHEMBL18936048 | 0.85 | L3MBTL1 (0.50) | TSHRTEAD3NAAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375749-A | Trans-alkenyl potassium trifluoroborate and synthesis method thereof | 西安近代化学研究所 | 2023-07-04 | — | — | CN | claimed |
| EP-2675805-B1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | INST CHEMII ORGANICZNEJ PAN (PL) | 2016-04-13 | — | — | EP | claimed |
| US-8884005-B2 | Method for the preparation of carbapenam compounds | Instytut Chemi Organicznej Pan (PL) | 2014-11-11 | — | — | US | claimed |
| US-20140148595-A1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | Instytut Chemi Organicznej Pan (PL) | 2014-05-29 | — | — | US | claimed |
| EP-2675805-A1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | Instytut Chemii Organicznej Pan (PL) | 2013-12-25 | — | — | EP | claimed |
| WO-2013067646-A1 | PROCESS FOR THE SYNTHESIS OF BETA-AMINOCARBONYLS | UNIVERSITY OF OTTAWA (CA) | 2013-05-16 | — | — | WO | claimed |
| WO-2012112061-A1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | INSTYTUT CHEMII ORGANICZNEJ PAN (PL) | 2012-08-23 | — | — | WO | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-04-23 | — | — | US | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| EP-0945448-A1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0722442-A1 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5120729-A | Enzyme inhibitors | MERCK & CO., INC. (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0462667-A2 | Beta-lactams as antihypercholesterolemics | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| US-4673672-A | ANTITUMOR AGENTS | SANDOZ PHARMACEUTICALS CORP. (US) | 1987-06-16 | — | — | US | disclosed |
| EP-0121972-A2 | N-aryl-alpha-amino-carboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | TSHR 2086/4885TEAD3 59/4885NAAA 4176/4885 |
| US-20140148595-A1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | SI, KPNA1, KPNA6 | TSHR 4843/4885TEAD3 3936/4885NAAA 123/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | TSHR 4254/4885TEAD3 64/4885NAAA 3015/4885 |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | LSS, F2R, CFTR | TSHR 697/4885TEAD3 2112/4885NAAA 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.